Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

2.17
+0.03001.40%
Volume:185.15K
Turnover:395.26K
Market Cap:31.13M
PE:-0.34
High:2.22
Open:2.21
Low:2.05
Close:2.14
52wk High:12.23
52wk Low:1.50
Shares:14.34M
Float Shares:9.27M
Volume Ratio:0.86
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3300
EPS(LYR):-19.4955
ROE:-203.63%
ROA:-56.86%
PB:4.67
PE(LYR):-0.11

Loading ...

Company Profile

Company Name:
Tempest Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
4
Office Location:
2000 Sierra Point Parkway,Suite 400,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Directors

Name
Position
Matthew Angel
Chief Executive Officer and Director and President
Stephen Brady
Chair of the Board and Director
Christine Pellizzari
Director
Michael Raab
Director
Ronit Simantov
Director

Shareholders

Name
Position
Matthew Angel
Chief Executive Officer and Director and President
Nicholas Maestas
Chief Financial Officer and Corporate Secretary and Head of Corporate Strategy
Justin Trojanowski
Corporate Controller and Principal Accounting Officer